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alpha-1, 5%; alpha-2, 18%; beta, 16%; gamma, 19%); serum
creatinine, 0.7 mg/dl; sodium, 135 mEq/liter; potassium, 4.2
mEq/liter; chloride, 96 mEq/liter; bicarbonate, 26 mEq/liter;
and glucose, 106 mg/dl. Liver function tests were normal. A
24-hour urine collection contained 10 g protein. The urinary
sediment showed 100,000 red blood cells/ml. Immunologic tests
were negative, except for the presence of antinuclear antibodies
(1:1000) but without anti-DNA antibodies. Ultrasonography
revealed no abdominal abnormality and two normal-sized kid-
neys.
A renal biopsy was performed. Light microscopic examina-
tion (Fig. 1A) showed only hypertrophy of some podocytes.
The capillary walls had a nearly normal appearance. Immuno-
fluorescent examination revealed, however, typical subepithel-
ial deposits brightly stained with anti-g (Fig. 1B), anti-k, and
anti-l antibodies. Droplets of polyclonal IgG and IgA also wereCASE PRESENTATIONS
seen in the cytoplasm of proximal tubules. Electron microscopyPatient 1. A 49-year-old white man was referred to the
confirmed the presence of small, granular, electron-dense de-Renal Division at Hoˆpital Tenon for investigation of nephrotic
posits on the outer aspect of the glomerular capillary basementsyndrome in the setting of bronchogenic carcinoma. Past medi-
membrane.cal history was unremarkable, except for two urinary tract
One week after biopsy, the patient was randomized afterinfections; an intravenous pyelogram performed six months
informed consent into the chemotherapy arm of a French pro-earlier had been normal. Three months before admission, ane-
tocol for the treatment of bronchogenic carcinoma. He receivedmia had been discovered together with an inflammatory syn-
a single course of chemotherapy without corticosteroid (mito-drome. The patient had recently lost 6 kg. He also complained
mycin, 6 mg/m2 at day one; cisplatin, 30 mg; and ifosfamide,of cough of recent onset, although he had a 25-pack-year history
1.5 mg/m2 from day one to day three), followed one monthof cigarette smoking. A chest radiograph revealed a dense
later by surgery. Pre-operative staging showed a 50% reductionopacity of the right lung apex. A CT scan showed that this
of the tumor mass but the persistence of high urinary proteinmass was located in the apico-dorsal segment of the right upper
excretion (7 g/day). Thoracotomy revealed a 7 cm in diameterlobe and was associated with enlarged lymph nodes and a
neoplastic mass without signs of lymph node invasion and me-pleural reaction. Bronchoscopy disclosed a necrotic tumor in
tastasis (stage T2, N0, M0). The patient then received threethe posterior and apical apertures of the right upper bronchus.
additional courses of the same chemotherapy regimen at one-Bronchial biopsies established a diagnosis of epidermoid bron-
chogenic carcinoma. month intervals.
On admission, the patient looked tired and pale. His blood A 24-hour urine collection contained 7 g protein eight days
pressure was 120/80 mm Hg. Physical examination was normal, after total excision of the carcinoma, but proteinuria totally
showing neither edema nor signs of tumor dissemination. Labo- disappeared within two months. It did not recur when the
ratory tests showed: hemoglobin, 12.4 g/dl; erythrocyte sedi- patient presented five months after surgery with a mediastinal
mentation rate, 86 mm/hr; total protein, 5.6 g/dl (albumin, 42%; lymph node relapse, which was controlled by cobalt therapy.
Three years after surgery, the patient is doing well, without
either proteinuria or other manifestation of tumor recurrence.
Presentation of this Forum is made possible by grants from Merck & Patient 2. A 59-year-old white man was referred to our
Company, Incorporated; Astra Pharmaceuticals; Hoechst Marion Renal Division for investigation of a nephropathy associated
Roussel, Incorporated; Dialysis Clinic, Incorporated; Amgen, Incorpo- with chronic lymphocytic leukemia (CLL). He had a 13-yearrated; Janssen-Cilag, Incorporated; and R & D Laboratories, Incorpo-
history of cold-induced swelling of his hands and face with arated.
pruriginous urticarial rash, which was highly sensitive to anti-
histamine drugs.Key words: nephrotic syndrome, membranous glomerulonephritis, IgA
nephropathy, crescentic glomerulonephritis, minimal change disease, Four years earlier, he had been referred to the Renal Division
amyloidosis, immunotactoid glomerulopathy, monoclonal immuno- of Saint-Quentin General Hospital (Saint-Quentin, France) for
globulin deposition disease, POEMS syndrome, Castleman’s disease. edema of the legs. Physical examination at that time disclosed
high blood pressure (190/110 mm Hg) and numerous small, 1999 by the International Society of Nephrology
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Fig. 1. Patient 1. (A) Light microscopy. Note discrete thickening of the glomerular capillary walls and mild podocyte hypertrophy (Masson trichrome;
original magnification 3 312). (B) Immunofluorescence with anti-g antibody. Note typical subepithelial deposits (original magnification 3 312).
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mobile lymph nodes in the right cervical and both inguinal either by immunofluorescence or by electron microscopy along
tubular basement membranes. Mesangial interposition wasareas, without liver and spleen enlargement.
Laboratory investigation revealed: BUN, 36 mg/dl; serum seen in rare lobules. A diagnosis of immunotactoid glomerulo-
nephritis with monotypic IgGk deposits was made.creatinine, 1.4 mg/dl; total protein, 6.7 g/dl; albumin, 3.7 g/dl;
hematocrit, 37%; cholesterol, 9.6 mmol/liter; and triglycerides, Chlorambucil and prednisone were continued for three
years, during which time the renal disease was well controlled.1.78 mmol/liter. Hemoglobin was 12.3 g/dl. The white blood
cell count was 14.2 3 106/ml with 70% lymphocytes. The plate- The patient died from sepsis.
Patient 3. A 58-year-old white man was referred to the Re-let count was 36 3 106/ml. The 24-hour urinary protein excre-
tion was 8 g, with 79% albumin. The urinary sediment con- nal Division of Chartres Hospital (Chartres, France) for evalua-
tion of edema. His medical record mentioned the detection oftained numerous red blood cells (450,000/ml) but no white
cells. Urine culture showed no growth. Immunologic studies hematuria a few years earlier during a routine checkup and
the recent onset of hypertension.disclosed hypogammaglobulinemia (0.5 g/dl) due to a de-
creased level of IgG (0.3 g/dl), and transient signs of comple- Clinical examination revealed a blood pressure of 170/100
mm Hg and edema of the legs. Laboratory tests showed ament consumption (CH50, 33%). No monoclonal component
was found in either the serum or the urine, and repeated hemoglobin of 12.7 g/dl, a white blood cell count of 6.3 3
106/ml, and a platelet count of 290 3 106/ml. Total serum proteinsearches for cryoglobulinemia were negative. A bone marrow
biopsy revealed diffuse infiltration by apparently normal, small was 3.2 g/dl, serum creatinine was 1.2 mg/dl, and glycemia was
in the normal range. Proteinuria was only 1.0 g/day. Liverlymphocytes. Numerous megakaryocytes were seen; a search
for anti-platelet antibodies was negative. Typing of blood function tests were normal. Because of marked hypoalbumi-
nemia (2.3 g/dl), tests for protein-losing enteropathy and mal-lymphocytes showed 65% B- and 20% T-lymphocytes. Chest
radiographs were normal. Ultrasonography revealed two nor- absorption were performed. All were negative, as was the
search for amyloid deposits in gastrointestinal biopsies. Hema-mal-sized kidneys, but no lymph node or liver enlargement.
However, lymphography disclosed diffuse, heterogeneous turia was present; there were 40,000 to 200,000 cells/ml. Serum
electrophoresis showed hypogammaglobulinemia (IgG, 0.23nodes without signs of lymphatic obstruction.
A diagnosis of CLL-related glomerulopathy was made, but g/dl; IgA, 0.19 g/dl; IgM, 0.035 g/dl), and immunoelectrophore-
sis disclosed a monoclonal IgGl in the serum and free l lighta renal biopsy could not be performed because of thrombocyto-
penia. The patient then received 12 courses of chemotherapy chains in the urine. The C3 and C4 complement levels were
in the normal range. Searches for cryoglobulinemia were fruit-including cyclophosphamide, adriamycin, vincristine, and pred-
nisone over a period of 18 months. Under this regimen, protein- less. A bone-marrow aspirate contained 14% dystrophic plasma
cells, consistent with multiple myeloma. Skeletal radiographsuria decreased to less than 2 g/day, renal function improved
(serum creatinine, 1.0 mg/dl), and abdominal lymph nodes dis- did not reveal osteolytic lesions.
A renal biopsy was performed. Light microscopic examina-appeared on lymphography, as did blood lymphocytosis. The
white blood cell count was 4 3 106/ml with 31% lymphocytes tion showed nodular glomerulosclerosis with a marked increase
in mesangial matrix and irregular thickening of glomerularat the end of chemotherapy, but the platelet count remained
low, between 63 and 76 3 106/ml. The patient was given nine basement membranes (Fig. 3A). Mesangial nodules were stained
with periodic acid Schiff. Only mild, focal thickening of tubularcourses of chlorambucil and prednisone over a one-year period.
For the first time, the platelet count increased above 100 3 basement membranes was present. No evidence of amyloid was
seen. Electron microscopy disclosed an expanded mesangial106/ml, and the patient was referred to our Renal Division for
a renal biopsy. matrix with deposition of finely granular, electron-dense mate-
rial within mesangial nodules. Glomerular basement membranesOn physical examination, the patient looked healthy. He had
no functional complaints or clinical abnormalities. Laboratory were irregularly thickened, due to a continuous band of granu-
lar, electron-dense material located in the lamina rara internastudies showed 3.6 3 106/ml white blood cells with 35% lympho-
cytes and 110 3 106/ml platelets; hemoglobin, 12.2 g/dl; total and/or in the lamina densa; this thickening often resulted in
dense transformation of the whole basement membrane (Fig.protein, 5.2 g/dl (albumin, 70%; alpha-2, 10%; gamma globu-
lins, 8%); creatinine, 0.7 mg/dl; creatinine clearance, 76 ml/ 3B). By immunofluorescence, mesangial nodules and glomeru-
lar basement membranes were heavily stained with the anti-gmin; normal liver function tests; and no cryoglobulin. Daily
urinary protein output had increased slightly (2 to 3 g/day), heavy chain conjugate (Fig. 4), but no staining was observed
with the anti-k or the anti-l polyclonal and monoclonal anti-but the urinary sediment was normal. A bone marrow aspirate
showed only 10% lymphocytes with a normal distribution of bodies. In addition, a faint staining of some tubular and vascular
structures was visible with the anti-g heavy-chain antibody.granular cells. No monoclonal component was detected in the
serum or the urine by sensitive immunofixation techniques. Furthermore, by using monoclonal antibodies specific for the
g heavy-chain constant domains, we found that the depositedHowever, a few blood cells showed cytoplasmic spots of g and
k chains by immunofluorescence. heavy chain belonged to the g1 subclass and lacked the CH1
domain (Fig. 4). The heavy chain in the circulating monoclonalA renal biopsy showed an atypical membranous glomerulo-
nephritis. Capillary walls were thickened and irregular, with IgGl was also a CH1-deleted g1 chain. Bone marrow studies
(J.C. Brouet, Hoˆpital Saint-Louis, Paris) were consistent withnumerous spikes after silver methenamine staining (Fig. 2A).
Four atypical features were noted, however. First, foci of mes- the synthesis of a short g heavy chain and normal-sized l
chains, which partly assembled covalently as half immunoglob-angial hypertrophy and cellular proliferation were visible (Fig.
2A). Second, the interstitium contained lymphocytic infiltrates. ulin molecules (composed of one l and one short g chain). A
diagnosis of myeloma-induced heavy chain deposition diseaseThird, immunofluorescent examination disclosed granular
monotypic IgGk deposits on the outer aspect of capillary walls was made.
The patient was subsequently begun on a chemotherapy(Figs. 2B–C), contrasting with the lack of circulating IgGk by
immunoelectrophoresis and immunofixation. Fourth, electron regimen including vincristine, melphalan, cyclophosphamide,
and prednisone, administered on a monthly basis for one year.microscopic evaluation disclosed that these subepithelial de-
posits had a fibrillary structure (Fig. 2D). They consisted of During that time, his proteinuria disappeared, serum albumin
returned to normal, and renal function remained stable. Amicrotubules with a diameter of 22 nm. There were no deposits
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Fig. 2. Patient 2. (A) Light microscopy. Atypical membranous glomerulonephritis: in addition to the irregular aspect of the capillary walls, note
segmental mesangial hypertrophy and cellular proliferation (silver stain; original magnification 3 312). (B, C) Immunofluorescence microscopy.
Diffuse granular deposits along the capillary walls with predominant subepithelial location. Staining was exclusive for IgG (B) and kappa light
chain (C, next page). Original magnification 3 312. (D) Electron micrograph of a glomerular capillary. Note subepithelial deposits of fibrillar
material cut at various angles. Uranyl acetate and lead citrate (original magnification 3 12,000. Reproduced from [46]).
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Fig. 2. Continued.
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Fig. 3. Patient 3. (A) Light microscopy. Nodular glomerulosclerosis. Note moderate mesangial hypercellularity, scarce double-contour aspects,
and normal appearance of most tubular basement membranes. PAS stain (original magnification 3 312). (B) Electron micrograph of a glomerular
capillary. Note diffuse, finely granular, electron-dense deposits along the glomerular basement membrane with effacement of epithelial cell foot
processes (uranyl acetate and lead citrate; original magnification 3 12,000).
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Fig. 4. Patient 3. Epitope analysis of g-chain deposits by indirect immunofluorescence. Monoclonal antibodies specific for g-chain constant domains
and for g1 heavy-chain were used. Deposits reacted with NL16, a monoclonal antibody specific for the g1 subclass. Note staining of the deposits
with anti-CH2 and anti-CH3 antibodies but not with the anti-CH1 antibody (original magnification 3 312).
second renal biopsy showed significant improvement of the lar link, and even specific molecular abnormalities, can
renal lesions. The patient’s treatment was then shifted to inter- be demonstrated in lymphoplasmacytic disorders.
feron a (9 3 106 units/week).
The concept of paraneoplastic glomerulopathy wasAfter more than five years of follow up, he has no evi-
introduced in 1922 by Galloway [1]. In 1939, Cornig indence of hematologic or renal disease. Immunoelectrophoresis
did not disclose any monoclonal component. Bone marrow Paris reported the first case of nephrotic syndrome and
smears showed 2% plasma cells with a normal appearance. Hodgkin’s disease in his M.D. thesis. The first convincing
Serum creatinine was 0.8 mg/dl; serum albumin, 3.8 g/dl; 24-
clinicopathologic study was published in 1966 by Lee ethour protein excretion less than 130 mg; and the urinary sedi-
al [2]. Of their 101 adult patients who presented withment was unaltered.
the nephrotic syndrome in a 10-year period, 11 (11%)
were found to have carcinoma; this percentage repre-DISCUSSION
sented 10 times the age-matched actuarial rate. Renal
Dr. Pierre M. Ronco (Chief, Division of Nephrology disease antedated the diagnosis of cancer in two-thirds
and INSERM Unit 489, Hoˆpital Tenon, Paris, France): of the study population. Of the 10 nephrotic patients with
The term paraneoplastic syndrome refers to clinical man- cancer in whom renal tissue was available, 8 had membra-
ifestations that are not directly related to tumor burden,
nous glomerulonephritis (MGN). In 1977, Eagen and
invasion, or metastasis, but are caused by the secretion
Lewis collected 171 cases of nephrotic syndrome associ-of tumor cell products such as hormones, growth factors,
ated with cancers including carcinoma, Hodgkin’s disease,cytokines, and tumor antigens. These three case reports,
non-Hodgkin’s lymphoma, leukemia, and plasma cell dys-all different forms of paraneoplastic glomerulopathy, ex-
crasia [3]. These studies highlighted the high prevalenceemplify the heterogeneity of this disease. Diverse glomer-
of MGN (34%) and minimal change disease (MCD,ular lesions occur in a variety of neoplasms; I will discuss
24%); the former was observed in 68% of the patientsseveral different pathophysiologic links between the glo-
with a carcinoma, the latter in 50% of those with Hodg-merulopathy and the cancer. The order of presentation of
kin’s disease. Other types of glomerular lesions werethe cases reflects our increasing level of pathophysiologic
described in this series and in more recent reports, in-knowledge: whereas the pathophysiology of solid-tumor-
associated glomerulopathies remains obscure, a molecu- cluding IgA nephropathy and Henoch-Scho¨nlein pur-
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Table 1. Renal complications of neoplasia (excluding Following the order of case presentations, I will analyze
paraneoplastic glomerulopathies)
first paraneoplastic glomerulopathies associated with
Mechanical (direct) carcinomas, then those induced by malignant hemopa-
Infiltration of renal parenchyma thies. The paraneoplastic origin of each glomerulopathyObstructive uropathy (retroperitoneal fibrosis)
will be discussed according to clinical (mainly temporal)Compression of renal artery or vein
Metabolic (indirect) criteria and presumed pathophysiologic links connecting
Nephrocalcinosis the cancer and the renal disease.Myeloma cast nephropathy
Electrolyte disturbances
Carcinoma-associated paraneoplastic glomerulopathiesDisseminated intravascular coagulation and thrombotic
microangiopathy Table 3 lists the distribution of carcinomas in three rep-Treatment-induced
resentative series of carcinoma-associated paraneoplas-Tumor lysis syndrome
Lithiasis and uric nephropathy tic glomerulopathies [3, 18, 19]. The most frequent glo-
Radiation nephropathy merulopathy by far is MGN. Associated carcinomasDrug-induced tubulointerstitial disease (cisplatin, antibiotics)
mostly occur in the lung and gastrointestinal tract. Al-Thrombotic microangiopathy and mesangiolysis
though this preponderance might be related to the over-
all frequency with which these neoplasms arise, other
common carcinomas, such as cancers of the breast and
uterus, have only rarely been associated with specific
pura, and membranoproliferative and crescentic glomer- glomerulopathies.
ulonephritis. Membranous glomerulonephritis. It is a rare disease
The prevalence of renal involvement in cancer patients (annual incidence of 2.8 per 100,000 over the age of 60)
has been analyzed in autopsy and clinical series. In the compared with cancer (annual incidence . 1,000 per
former, mesangial and subendothelial immunoglobulin 100,000 in the same age period). Thus the finding of
(Ig) deposits were observed in 11 of 20 patients (55%) carcinoma in a patient with MGN forces us to question
by Pascal and associates [4] and in 22 of 129 patients the link between the neoplasia and the glomerulopathy.
(17%) by Beaufils and colleagues [5]. I should stress, Brueggemeyer and Ramirez calculated that the inci-
however, that glomerular lesions were absent or mild, dence of cancer in their population of 128 MGN patients
limited to mesangial hypertrophy, and no epimembra- was about 10 times higher than that observed in age-
nous deposits were noted. matched controls [20]. However, it is intriguing that
In two clinical series, the prevalence of renal involve- subepithelial deposits were not found or were found very
ment was low [6, 7]. Urinary protein excretion greater infrequently in autopsy series of cancer patients [4, 5;
than 100 mg/liter and hematuria were detected in 10% reviewed in 21].
and 7%, respectively, of 600 patients with bronchial car- Theoretically, the diagnosis of paraneoplastic glomer-
cinoma [6]. In another study [7], proteinuria greater than ulopathy should rely on three strong criteria. First, a
0.1 g/liter was more common in patients with malignan- clinical and histologic remission occurs after complete
cies (174/504, 34%) than in control patients (39/529, 7%). surgical removal of the tumor or chemotherapy-induced
Median urinary protein concentrations were 0.14 (0.07 complete remission of the disease. However, relatively
to 0.29) g/liter in the former, and 0.07 (0.05 to 0.12) g/liter few papers have reported remission of MGN following
in the latter. However, the rates of renal manifestations removal of a solid tumor [reviewed in 19]. This finding
in these studies overestimate the actual prevalence of probably is due to the fact that the majority of carcino-
paraneoplastic glomerulopathies for at least three rea- mas associated with MGN are surgically incurable at
sons. First, the threshold of proteinuria selected by the presentation. Moreover, in patients showing remission
authors was quite low, within the range of physiologic of the nephrotic syndrome, like Patient 1, histologic cure
proteinuria. Second, hematuria was detected by qualita- of the glomerulopathy is usually not verified by a renal
tive dipstick tests only, without quantitation of the uri- biopsy for ethical reasons. Thus, one cannot exclude
nary sediment. Third, paraneoplastic glomerulopathies spontaneous remission of the nephrotic syndrome de-
are not the only cause of urinary abnormalities in cancer spite persistent subepithelial membranous deposits. I
patients (Table 1). should stress that spontaneous remission of the nephrotic
Conversely, the prevalence of cancer in patients with syndrome occurs in about 30% of patients presenting
glomerulopathies is easier to establish (Table 2). Cancer with idiopathic MGN within one year of follow up [22].
occurs in 11% to 13% of patients with the nephrotic Second, a renal relapse accompanies recurrence of the
syndrome [2, 8]. Depending on the age of the patients neoplasia. In other words, proteinuria should directly
and the type of glomerular lesions, cancer rates can reach correlate with tumor activity. In fact, the course of cancer
as high as 22% in patients over the age of 60 presenting and glomerulopathy can be dissociated, as in the first
patient, who presented with a mediastinal lymph nodewith MGN [8].
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Table 2. Prevalence of carcinomas and hemopathies in patients with glomerulopathies
Number of Prevalence of
Syndrome or lesions patients cancers (%) Authors and years
Nephrotic syndrome 101 11a Lee et al, 1966 [2]b
76c 13 Zech et al, 1982 [8]
Membranous GN 82 6 Hopper, 1974 [9]
66 11 Row et al, 1975 [10]
92 8 Chavaz et al, 1977 [11]
82 5 Cahen et al, 1989 [12]
107 8 Burstein et al, 1993 [13]
31c 22 Zech et al, 1982 [8]
24c 13a Kingswood et al, 1984 [14]
Crescentic GN 60 7a Whitworth et al, 1976 [15]
80 9 Biava et al, 1984 [16]
IgA nephropathy 184 3a Mustonen et al, 1984 [17]
26c 23a Mustonen et al, 1984 [17]
a All carcinomas
b Figure in brackets is reference number. Series are classified in chronologic order
c Patients over the age of 60 years
Table 3. Prevalence (%) of MGN and distribution (%) of carcinomas in three series of paraneoplastic glomerulopathies
Eagen and Lewis [3] Mignon et al [18] Pai et al [19]
n 5 67a n 5 37 n 5 16
MGN, %b 69 68 44
Location of cancer
Lung 49 43 50c
Gastrointestinal tract 23 11 31c
Breast 4 8 6
Kidney 5 11 6
Prostate 0 5 6
Head and neck 7 8 —
Other 12 14 6
a Location of cancer was available in 57 patients
b MGN: membranous glomerulonephritis
c One patient with both gastric carcinoma and lung metastasis
relapse in the absence of proteinuria. Third, a pathophys- those of idiopathic MGN, although several authors have
noted the presence of numerous polymorphonuclear leu-iologic link is established between the two diseases, in-
cluding the detection of tumor antigens and antitumor kocytes in capillary loops, occasionally associated with
intravascular hyaline thrombi in the absence of renalantibodies within subepithelial immune deposits. Very few
cases of MGN involving such immune complexes have vein thrombosis [18].
Although it is generally agreed that a search for malig-been reported so far, however. Alpers and Cotran conse-
quently have suggested that the association between ma- nancy is warranted in all patients presenting with appar-
ently idiopathic MGN, particularly those over the agelignancy and MGN has been overemphasized [21].
In patients in whom the diagnosis of paraneoplastic of 50, the extent of the workup remains controversial. I
believe that in addition to a thorough history of theMGN is likely because of a clear temporal relationship
between MGN and malignancy, the following features patient with a search for personal and hereditary cancer
risk factors, physical examination, and standard biologicof the renal disease are notable. Compared to idiopathic
forms, paraneoplastic MGNs are characterized by a tests, one should undertake basic routine cancer screen-
ing procedures, including a chest radiograph and a flexi-marked male preponderance, mean age over 50, and a
full-blown nephrotic syndrome always present. Of the ble colonoscopy. Further investigation, including flexible
bronchoscopy or gastroscopy and CT scan, might be inpatients with carcinoma and MGN, 40% to 45% clini-
cally manifest the nephrotic syndrome prior to the diag- order after this first-line evaluation. More important,
these patients should be closely followed, as the malig-nosis of their tumor. Simultaneous presentation occurs
in about 40% of patients, and in the remaining 15% to nancy could be occult and not detectable on initial rou-
tine screening.20%, renal disease becomes apparent following diagno-
sis of their tumor. In the majority of cases, the two pro- Other carcinoma-associated glomerulopathies. Mem-
branous glomerulonephritis is not the only paraneoplas-cesses manifest themselves within 12 months of each
other [2, 3, 13, 18, 19]. The renal lesions are similar to tic glomerulopathy (Table 2). Other varieties include
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IgA nephropathy, crescentic glomerulonephritis, mem- tions is too small (,20) for one to conclude that a causal
relationship exists betweeen carcinoma and the renalbranoproliferative glomerulonephritis (MPGN), and min-
imal-change disease (MCD). The IgA nephropathies de- disease [reviewed in 26, 27].
Carcinoma-associated amyloidosis deserves specialserve special comment. These lesions can be limited to
the kidney or associated with Henoch-Scho¨nlein pur- discussion. Approximately 3% of renal cell carcinomas
are associated with AA-type amyloidosis [reviewed inpura; one should suspect paraneoplastic IgA nephropa-
thy if the patient has necrotic skin lesions in the absence 28]; this systemic complication not only causes the ne-
phrotic syndrome, but also liver and spleen involvement.of cryoglobulin. Of 26 patients aged 60 or older, 6 (23%)
had an intercurrent malignancy in Mustonen et al’s se- Of all carcinomas associated with amyloidosis, 25% to
33% are renal cell carcinomas, yet this tumor accountsries, whereas none of the 158 patients under age 60 had
cancer (Table 2) [17]. Any IgA nephropathy in a patient for only 2% to 3% of all carcinomas. The production of
IL-6 by renal tumor cells could account for the feverover age 60 should prompt a search for a solid tumor,
particularly in the respiratory tract, the buccal cavity, and and chronic inflammation frequently observed in these
patients. Remission of the nephrotic syndrome can occurthe (naso)pharynx [17]. This association can, however, be
fortuitous or be strengthened by alcoholism, which is a following nephrectomy. Renal amyloid deposits, how-
ever, seem more persistent than are liver and spleenrisk factor for both hepatopathy-induced IgA nephropa-
thy and cancers of the upper respiratory tract. It is inter- deposits. More recently, cases of nonamyloid fibrillary
glomerulopathy have been reported in patients with gas-esting that mesangial IgA deposits were found at autopsy
in some individuals with gastrointestinal neoplasia with- tric adenocarcinoma or metastatic adenocarcinoma of
the liver [reviewed in 29].out prior clinical evidence of renal disease [5]. Mustonen
et al have suggested that invasion of mucosa by tumor Pathophysiology of paraneoplastic glomerulopathies in
carcinoma patients. Now I would like to discuss the patho-cells raises the level of circulating IgA and possibly pro-
duces mesangial IgA deposits [17]. genesis of paraneoplastic glomerulopathies with granular
immune deposits, mainly membranous glomerulopathy.Several reports strongly suggest an association be-
tween rapidly progressive glomerulonephritis and carci- Despite considerable efforts in many laboratories, in-
cluding ours, identification of the human antigens impli-noma (and lymphoplasmacytic disorders); the prevalence
of cancer was 7% to 9% in patients with a pathologic cated in primary (idiopathic) membranous glomerulopa-
thies has been unsuccessful. Although megalin, the targetdiagnosis of crescentic glomerulonephritis (Table 2) [15,
16]. In four of the seven patients reported by Biava et antigen of Heymann’s nephritis—a faithful model of
membranous nephropathy in the rat—is expressed onal, renal function improved following treatment of the
underlying malignancy, which only consisted of surgery the brush border of the human proximal tubule, it is
not detected on the human podocyte [30]. Megalin thusand/or irradiation in three of them [16]. In most in-
stances, as in Biava’s patients, immunofluorescent exami- cannot serve as a target antigen for circulating antibodies
in the human glomerulus as it can in the rat. But megalinnation shows fibrin deposits without immune reactants.
In other cases, granular or linear immunoglobulin depos- might be an antigenic component of nephritogenic circu-
lating immune complexes in renal-cancer-associated glo-its are seen [15, 18, 19]. One patient with prostatic carci-
noma had a crescentic glomerulonephritis with positive merulopathies. Ozawa and associates detected the renal
brush-border lipoprotein antigen RTE (an antigenic mix-immunoperoxidase staining for both prostate-specific
acid phosphatase and prostate-specific antigen, as well ture containing megalin) in glomerular deposits and anti-
RTE antibodies in the serum from the same three patientsas immune deposits on electron microscopy in the glo-
merulus [23]. Of particular interest are four patients who [31], but their findings have not been confirmed yet.
Paraneoplastic glomerulopathies theoretically repre-presented with rapidly progressive glomerulonephritis,
clinical evidence of vasculitis, and positive ANCA serol- sent an attractive model for unraveling the pathogenesis
of membranous glomerulonephritis because carcinomasogy [24]. In all four patients, a carcinoma of either the
respiratory or urinary tract was diagnosed soon after the are important sources of antigens that can prompt the
production of specific antibodies. Both tumor antigensfinding of ANCAs, suggesting the paraneoplastic nature
of the vasculitic process. and the respective antibodies can associate in blood as
immune complexes, which can subsequently deposit inMembranoproliferative glomerulonephritis and mini-
mal change disease also occur in patients with carcinoma, tissues including the kidney; alternatively, tumor anti-
gens with high affinity for basement membrane constit-although these lesions are more typical of lymphoproli-
ferative disorders; MPGN has been reported in patients uents can become planted into the glomerular capillary
wall, and then participate in in-situ formation of immunewith Wilms’ tumor and malignant melanoma [25]. Mini-
mal change disease has been associated with a variety of complexes with free circulating antibodies. Numerous
attempts have been made to identify tumor antigens orcarcinomas; although the nephrotic syndrome can remit
completely after surgery [26], the number of observa- their specific antibodies in kidneys of cancer patients.
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Table 4. Immunopathologic data in paraneoplastic glomerulopathies
Location Number Type of Deposited Reactivity of
of cancer of cases glomerulopathy antigen eluted Ig Reference
Lung 1 MGNa NIb Tumor antigen [32]
Colon 1 MGN CEAb NI [33]
Colon 1 MGN Tumor antigen NI [34]
Lung 1 MGN NI Normal lung tissue [35]
and tumor antigen
Stomach 3 MGN CEA CEA [36]
(2 patients) (or CEA-like antigen)
Palate 1 MGN CEA NI [37]
Melanoma 1 MPGN Tumor antigen Tumor antigen [25]
Prostate 1 Crescentic PSAP/PSAb NI [23]
Kidney (clear cell) 3 Deposits RTEb Nurmal brush border,c [31]
jejunal mucosa,c
tumor cell membranesc
Stomach 1 Deposits CEA CEA [38]
a MGN: membranous glomerulonephritis; MPGN, membranoproliferative glomerulonephritis
b NI: not identified; CEA, carcinoembryonic antigen; PSAP, prostatic-specific acid phosphatase; PSA, prostatic-specific antigen; RTE, renal tubule epithelium antigen
c All containing the lipoprotein antigen RTE. Kidney eluates from only 2 patients contained Ig and could be further studied for their reactivity
To my knowledge, tumor antigens or antibodies have the p53 protein is a potentially good candidate because
different mutations of this genome-guarding moleculebeen demonstrated in no more than 14 cases of paraneo-
plastic glomerulopathy (Table 4). Tumor antigens impli- are known to occur depending on the location and type
of cancer, the mutations resulting in production of anti-cated in the formation of immune deposits have been
the carcinoembryonic antigen, prostate-specific antigens, p53 antibodies [39].
the renal antigen RTE, and other unidentified tumor
Hemopathy-induced paraneoplastic glomerulopathiesproducts. Tumor antigens and their corresponding anti-
bodies were associated in glomeruli in only seven pa- The paraneoplastic nature of these renal lesions is easier
to establish than are carcinoma-associated glomerulopa-tients [25, 31, 36, 38]. Four of these patients, however,
had only mild glomerular lesions or none at all and no thies because of the higher rate of complete remission
of the malignant hemopathy, and because of the molecu-subepithelial deposits [31, 38].
The presence of tumor antigens and their correspond- lar link between the hemopathy and the glomerulopathy,
often a monoclonal immunoglobulin, which provides aing antibodies in patients with paraneoplastic glomerulo-
pathies does not mean, however, that they are involved clear pathophysiologic explanation to the renal lesions
observed. This distinction is well illustrated by Patientsin the initial pathogenetic process leading to the formation
of immune deposits. Indeed, these components can be- 2 and 3.
Hodgkin’s disease. The association between Hodgkin’scome passively deposited because of increased glomeru-
lar permeability to proteins as a result of the initial insult. disease and glomerulopathy is probably the best known
of the hemopathy-induced paraneoplastic glomerulopa-Let me summarize. As Alpers and Cotran emphasized
[21], although it is likely that cancer-associated membra- thies, although in two large series collecting 1,700 Hodg-
kin’s disease patients, only 0.4% of them had MCD andnous glomerulonephritis is immune-complex-mediated,
the limitations of the immunologic studies performed, only 0.1% amyloidosis [40, 41]. In a more recent review,
Moulin et al [42] have identified approximately 100 re-the high prevalence of circulating immune complexes,
and the frequent deposition of non-pathogenetic glomer- ports of Hodgkin’s-disease-associated glomerulopathy,
mainly amyloidosis (37%) and MCD (42%) (Table 5).ular immune reactants in patients with cancer have made
it difficult to pinpoint tumor-associated antigens as the It must be noted, however, that most case reports of
amyloidosis were published before 1970 and occurredprimary initiators of glomerular injury. To further ana-
lyze the implication of tumor antigens in paraneoplastic late in the course of the disease. The markedly decreased
incidence of amyloidosis in Hodgkin’s disease is mostglomerulopathies, these antigens must be identified at
the molecular level, and experimental models must be likely attributable to modern treatment protocols, which
induce a rapid remission of the hemopathy. Franklin etdeveloped in animals immunized with a pure molecular
species. Alternatively, it is possible that immune pertur- al identified the type of amyloid deposit as AA [44]. We
can assume that most, if not all, cases of amyloidosisbations in cancer patients (that is, their producing anti-
bodies to exogenous or endogenous antigens) make these previously reported were of the AA type because they
occurred in late, inflammatory stages of the disease inindividuals prone to developing immune-complex nephri-
tis. Among the myriad possible endogenous antigens, the absence of an M-component.
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Table 5. Glomerular diseases associated with Hodgkin’s disease, B-chronic lymphocytic leukemia (B-CLL), and non-Hodgkin’s lymphoma
Hodgkin’s diseaseb B-CLL and low-grade B-lymphomac Non-Hodgkin’s lymphomad
Glomerular lesionsa Number of patients
Amyloidosis 39 (37%) 2 2
MCD 45 (42%) 4 5
FSG 4 4 3
MGN 5 7 5
MPGN 2 18 12
ExGN 6 3 12
Other PGN 5 3 3
IgA GN 0 0 3
MIDD 0 3 0
Immunotactoid GN 0 4 (3)e 4 (2)e
Total 106 45 47
a Abbreviations are: MCD, minimal change disease; FGS, focal segmental glomerulosclerosis; MGN, membranous glomerulonephritis; MPGN, membranoprolifera-
tive glomerulonephritis; ExGN, extracapillary glomerulonephritis; PGN, proliferative glomerulonephritis; MIDD, monoclonal immunoglobulin deposition disease
b [3, 21, 40–43]
c [3, 21, 42, 46–48]
d [3, 21, 42, 43, 49]
e Figure in parentheses refers to number of cases classified as membranous glomerulonephritis and immunotactoid glomerulopathy
At present, the most frequent glomerulopathy is MCD. eases have been greatly facilitated by the development
of sensitive techniques for the characterization of circu-In MCD, the nephrotic syndrome usually appears early,
revealing the disease in about one-half the cases and some- lating, urinary, and membrane immunoglobulin, and by
immunohistochemical and ultrastructural studies of renaltimes even preceding it by several months; it rapidly dis-
appears after effective treatment of Hodgkin’s disease, biopsy. Contrary to glomerular lesions observed in plasma
cell dyscrasias, which are well identified and usually re-even if corticosteroids are not used; and it usually re-
lapses simultaneously with the hemopathy, generally re- ported as series, those occurring in CLL have long been
reported only as isolated cases. We published in 1992maining highly responsive to specific treatment for the
cancer. Renal manifestations also can occur in patients the first series of 13 cases [46]; I have further reviewed
32 published observations for this Forum, thus establish-with hematologic relapse even if these manifestations
were initially absent. Followup of Hodgkin’s disease ing the relative prevalence of the various glomerular
lesions (Table 5). In CLL and related low-grade B-celltherefore should include evaluation for proteinuria. No
particular subgroup of Hodgkin’s disease patients, with lymphomas, MPGN and MGN are the most frequent
glomerulopathies; extracapillary glomerulonephritis isregard to age, gender, or stage of the disease, appears
to be more likely to develop MCD. However, MCD rare by comparison with non-Hodgkin’s lymphomas.
The CLL-associated glomerulopathies generally fulfillseems to be more frequent in “mixed cellularity” forms
of Hodgkin’s disease [45]. the three criteria required for the diagnosis of para-
neoplastic syndromes. First, they often reveal CLL and,Other glomerulopathies have been described in associ-
ation with Hodgkin’s disease, albeit with lower frequency as in Patient 2, the diagnosis of both diseases is made
simultaneously in about 50% of patients. Nephrotic syn-(Table 5). Six patients developed extracapillary glomerulo-
nephritis with anti-glomerular-basement-membrane anti- drome is present in 85% of patients and is associated with
renal failure in 33%. Second, these glomerulopathies arebodies [reviewed in 42]. The pathogenesis of this associa-
tion remains obscure but could involve the release and highly sensitive to the chemotherapy used to control
CLL. It is remarkable that of the nine successfully treatedpresentation of basement membrane nephritogenic epi-
topes or an abnormal immune response induced by Hodg- patients (for their hematologic disease) in our series,
seven had full remission of their nephrotic syndrome,kin’s disease.
Most studies devoted to the pathophysiology of glomer- and renal function improved in seven, remaining stable
in the two other patients. In five of the nine patients,ular lesions in Hodgkin’s disease have focused on MCD.
They support the hypothesis that an alteration in T-lymph- these results were obtained with chlorambucil alone, a
drug ordinarily not effective in idiopathic MPGN andocyte function responsible for abnormal lymphokine pro-
duction increases vascular permeability and leads to the MGN. This finding strongly suggests that improvement
of the glomerulopathy was mainly due to control of thenephrotic syndrome. The putative hyperpermeability
factor of lymphocytic origin remains unidentified. hematologic disease. Third, a dysproteinemia was de-
tected in about one-half of the patients in whom it wasChronic lymphocytic leukemia (CLL) and related B-cell
lymphomas. Studies on glomerulopathies in these dis- sought. This alteration consisted of a cryoglobulin in nine
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cases, and of a non-cryoprecipitating M-component in circulating lymphocytes suggested yet undefined physi-
cochemical anomalies of the M-component that lead toeight. Such a high percentage of dysproteinemia con-
trasts with its low incidence in CLL without renal involve- its rapid deposition [52]. They proposed the term “glo-
merulonephritis with organized microtubular mono-ment (5% to 10%). These immunologic anomalies pro-
vide a link between the B-cell clone responsible for the clonal immunoglobulin deposition” (GOMMID) for this
novel CLL-associated paraneoplastic glomerulopathy.hematologic disease and the glomerulopathy.
From a pathophysiologic point of view, patients who Additional cases have been reported in non-Hodgkin’s
low-grade lymphomas. Finally, in a third group of pa-have CLL with renal involvement illustrate the heteroge-
neity of paraneoplastic glomerulopathies and underline tients presenting with various glomerular lesions (includ-
ing FSG, crescentic GN, and advanced fibrotic lesions)the necessity for sophisticated immunopathologic analy-
ses to dissect the mechanisms at play. Schematically, pa- and neither cryoglobulin nor monotypic glomerular de-
posits, a clear-cut pathophysiologic link between CLLtients can be divided into three groups. The first group
includes patients with MPGN caused by cryoglobulinemia, and the glomerulopathy could not be established [46].
Plasma cell dyscrasias. Various types of glomerular dis-mostly type II. The existence of type-I or type-II cryo-
globulinemia is not surprising in a lymphoproliferative eases occur in patients with plasma cell dyscrasias (PCD).
These diseases can be classified into two categories bydisorder such as CLL, in which the B-lymphocyte clone
can be secretory. Cryoglobulins can be considered im- electron microscopy. The first, characterized by orga-
nized deposits, includes diseases with fibrillar deposits,mune complexes in which the antigen is a polyclonal
immunoglobulin (type-II or type-III cryoglobulin) or re- mainly amyloid light-chain (AL) amyloidosis, and dis-
eases with microtubule formation such as cryoglobuli-mains of undetermined nature (type-I cryoglobulin). In
the case of type-II and type-III cryoglobulins, the poly- nemic glomerulonephritis. The second category, which
mostly includes MIDD, is defined by non-organized de-clonal immunoglobulin itself is endowed with antibody
activity that is most often not identified. Gilboa et al posits usually exhibiting a granular appearance. The most
frequent glomerulopathy in PCD is AL amyloidosis,made an interesting observation in two patients with CLL
associated with MPGN, hypocomplementemia, and type-I found in about 11% of myeloma patients at autopsy [55].
Amyloid light-chain amyloidosis fulfills the criteria of acryoglobulinemia composed of an IgGk M-component
[50]. Their finding that immunoglobulin eluted from both truly paraneoplastic disease: it often reveals the PCD;
the precursor of amyloid fibrils is the light chain, mostlythe glomeruli and the serum cryoglobulin bound in vitro
to patients’ glomeruli but not to normal glomeruli sug- l, produced by the plasma cell clone; and regression of
amyloid deposits can be observed when the secretinggested that the monoclonal IgGk was directed to non-
glomerular antigens. The latter might be lymphocyte clone is eradicated, mainly by intensive chemotherapy
with the support of syngeneic bone-marrow transplanta-antigens as suggested by Day and colleagues [51] or non-
lymphocyte antigens, including viral antigens. On the tion or blood stem-cell autografting [56]. I will not detail
the characteristics of amyloidosis because it is a well-other hand, because of cryoglobulin’s ability to precipi-
tate in vessels under certain circumstances, we also known entity [reviewed in 57, 58].
It has been known since the late 1950s that nonamy-should suspect a direct pathogenetic role for it, irrespec-
tive of cryoglobulin composition. loidotic forms of glomerular disease resembling the le-
sion of diabetic glomerulosclerosis also could occur inThe second group, to which Patient 2 belongs, is char-
acterized by monotypic immunoglobulin deposits in the multiple myeloma. The presence of monoclonal light
chains in these lesions was recognized later by Randallabsence of cryoglobulinemia, with or without a circulating
M-component. Some of these patients present with fea- et al, who published the first description of light-chain
deposition disease (LCDD) [59]. The finding of bothtures typical of monoclonal immunoglobulin-deposition
disease (MIDD) with nodular glomerulosclerosis stained monoclonal heavy chains and light chains in the tissue
deposits from some patients defined light- and heavy-with the anti-k or anti-l light-chain antibody [47]. Others
have an atypical form of MGN, usually with thick, fibril- chain deposition disease (LHCDD). More recently, de-
posits containing monoclonal heavy chains only (HCDD),lary deposits seen on electron microscopy [52, 53]. The
microtubular aspect of the deposits and the absence of that is, in the absence of detectable light chains, were
observed in patients with otherwise typical Randall’stubular basement membrane staining with anti-light-
chain antibodies distinguish these cases from MIDD, in disease [60]. In clinical and pathologic terms, LCDD,
LHCDD, and HCDD are basically similar and are there-which the deposits display a granular pattern; instead
these alterations recall the ultrastructural lesions de- fore also referred to as monoclonal immunoglobulin de-
position disease. They differ from amyloidosis by theirscribed in immunotactoid glomerulopathy. Korbet et al
reported one patient with immunotactoid glomerulopa- lack of affinity for Congo red stain and by the lack of
fibrillar organization of the deposits, which usually dis-thy and CLL [54]. Touchard and associates’ finding of
organized microtubular structures in the cytoplasm of play a granular appearance on electron microscopy. An
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Table 6. Prevalence of clinical manifestations and glomerular lesions in monoclonal immunoglobulin-deposition disease (MIDD)
Number of Male/Female Age, years Renal Nephrotic Nodular
Type of MIDD patients ratio (range) Hypertension failureb syndrome Hematuria glomerulosclerosis
LCDD and LHCDDa 64 1.6 54 55% 89% 44% 44% 61%
(31–77)
HCDDa 12 2.0 57 82% 83% 58% 100% 100%
(35–79)
a LCDD and LHCDD data from Refs. 63–66; HCDD data reviewed in Ref. 58
b Serum creatinine . 130 mmol/liter
Table 7. Light-chain peculiarities associated with amyloidosis andextensive description of LCDD appears in several re-
light-chain deposition disease (LCDD)
views [59, 61, 62]. Clinical manifestations are summa-
Amyloidosis LCDDrized in Table 6 from the four largest series yet published
Predominant isotype l k[63–66]. Table 6 also shows the clinical data in the 12
Variability subgroup VlVIa VkIVaknown cases of HCDD [reviewed in 58]. The higher
Size abnormalities Fragments in urine Short or large light
prevalence of hypertension, nephrotic syndrome, and chains (glycosylation)b
Amino acid residueshematuria might be accounted for by the greater severity
exposed to solvent Acidic Hydrophobicof renal lesions; nodular glomerulosclerosis was ob-
Interaction with Extracellular matrix —
served in all patients with HCDD. componentsc
Monoclonal immunoglobulin-deposition disease is a a All VlVI light chains are amyloidogenic. Not all VkIV light chains induce
LCDDparaneoplastic systemic disease that affects basement
b Glycosylation correlates with the lack of circulating and urinary light chainsmembranes in most tissues, although the distribution by sensitive detection techniques as observed in about 20% of LCDD patients
c Reactivity with extracellular matrix components may be explained by highcan be more restricted in HCDD. The most common
dimerization constant and antibody-like behavior of the V-domainunderlying disease is myeloma, which accounts for 40%
to 50% of LCDD and 25% of HCDD. Autopsy revealed
MIDD in about 5% of myeloma patients [55]. Other
malignancies occasionally involved are CLL and Wal- In our patient as well as in the 6 others [68] in whom a
denstro¨m’s macroglobulinemia. Like AL amyloidosis, structural analysis of the heavy chain was performed
MIDD also can occur in the absence of a detectable either by epitope mapping of the constant domains of the
malignant process, even after prolonged follow up circulating or the deposited heavy chain or by sequence
(longer than 10 years). This finding illustrates that the analysis [69], a deletion of the first constant domain CH1
same disease can be induced by a light chain produced was observed. In the blood the deleted heavy chain was
by either a malignant or a benign plasma-cell clone; thus associated with light chains, mostly of the l isotype, or
paraneoplastic-like glomerulopathies can occur with be- circulated in small amounts as a free unassembled sub-
nign proliferation. At least two retrospective studies unit. Since the retention of free heavy chains in the
have shown the potential renal benefits of chemotherapy endoplasmic reticulum before their association with light
[66, 67] although, as for amyloidosis, regression of light- chains requires binding of chaperone proteins to the CH1
chain deposits is rarely observed. domain, we can deduce that the CH1 deletion facilitates
Monoclonal immunoglobulin-deposition disease pro- the secretion of free unassembled or partially assembled
vides a unique opportunity for analysis of the pathogene- heavy chains that are rapidly cleared from the circulation
sis of some paraneoplastic glomerulopathies at the mo- by organ deposition. Although deletion of the CH1 seems
lecular level, because the nephritogenic molecule is a to be necessary for the development of HCDD, the dele-
monoclonal immunoglobulin subunit. In LCDD, several tion is not sufficient. Similar deletions indeed are found
characteristics of light chains might partially explain their in heavy-chain disease, a lymphoproliferative disorder
pathogenicity [reviewed in 58]. Table 7 compares these in which renal tissue deposition of the truncated heavy
characteristics with those of amyloidogenic light chains, chains has not yet been documented, and in AH amy-
because different physicochemical properties of these loidosis, in which deposits have a fibrillar organization
molecules are likely responsible for the granular (in [69]. These data suggest that the variable domain of the
MIDD) or fibrillar (in amyloidosis) aspect of the deposits heavy chain (VH) is also required for tissue precipitation.
[reviewed in 58]. Although a monoclonal component usually represents
Patient 3, who had myeloma-induced HCDD, shows the molecular link between the plasma cell proliferation
that a detailed analysis of the serum and the renal biopsy and the glomerulopathy in PCD, there are puzzling ex-
with specific anti-constant domain antibodies can pro- ceptions characterized by the occurrence of severe glo-
merulonephritis in the absence of M-component deposi-vide further insight into the pathogenesis of the disease.
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tion. The best example is the glomerulopathy of POEMS could identify the molecular link. In particular, this would
allow us to dispel the doubts cast by several authors onsyndrome, also called Crow-Fukase syndrome, a multi-
systemic disorder characterized by polyneuropathy, or- the truly paraneoplastic nature of these glomerulopathies,
and to better delineate the risk of inducing renal diseaseganomegaly, endocrinopathy, monoclonal protein, and
skin changes [70]. A variety of glomerular alterations in cancer patients treated by antitumor vaccination.
have been described, including MPGN-like, microangio-
pathic, and mesangiolytic lesions, but without deposition
QUESTIONS AND ANSWERS
of the M-component [71]. In the forms with a localized
Dr. John T. Harrington (Dean, Tufts Universityplasmacytoma, removal of the tumor induced dramatic
School of Medicine, Boston, Massachusetts): The com-improvement of the clinical manifestations. The role of
mon theme in all these patients is proteinuria secondarygrowth factors, including interleukin-6 and vEGF [72,
to increased glomerular permeability. Could you specu-73], has been proposed to explain endothelial prolifera-
late on the lymphokines that might be involved? Second,tion and associated vascular lesions. POEMS-related glo-
have serum or cells from patients with Hodgkin’s diseasemerulopathies share common features with Castleman’s
and MCD been shown in experimental tissue systems todisease, a lymphoproliferative and vascular disorder that
increase basement membrane permeability?is sometimes associated with POEMS syndrome. The
Dr. Ronco: The most appropriate neoplasia for dis-finding of human herpesvirus-8 (HHV-8) in about 40%
cussing the role of lymphokines as permeability factorsof non-HIV patients with Castleman’s disease [74] and
is a` priori Hodgkin’s disease because proteinuria usuallythe angiogenesis-activating properties of HHV-8, the
occurs in the absence of glomerular lesions and alsoKaposi’s sarcoma-associated herpesvirus (KSHV) [75],
because lymphokines have been involved in several man-suggest that HHV-8/KSHV is implicated in the patho-
ifestations of the disease. However, the view that Hodg-physiology of vascular lesions.
kin and Reed-Sternberg cells, which both have beenNon-Hodgkin’s lymphoma (NHL). Patients with NHL
assigned to the B-cell compartment [76], increase glo-manifest a great variety of glomerular lesions (Table 5)
merular permeability via the secretion of a single lym-[49]. Contrary to the observations made in Hodgkin’s
phokine is far too simplistic. First, Hodgkin and Reed-disease, MCD is rare in NHL; the most frequent glomer-
Sternberg cells usually make up less than 1% of theulopathies are MPGN and crescentic glomerulonephritis.
tumor cell mass, which is mainly composed of a polymor-Because of the diversity of renal lesions, an important
phic cellular infiltrate comprising T-cells, eosinophils,question is whether the association between NHL and
neutrophils, plasma cells, histiocytes, and fibroblasts inglomerulonephritis is coincidental. As for CLL, a clear-cut
close vicinity to the malignant cells. Second, a great vari-relationship can be established in patients with cryoglob-
ety of lymphokines and growth factors (IL-1, IL-2, IL-4,ulinemic MPGN and in those with immunotactoid glomer-
IL-6, IL-7, IL-9, IL-12, TNF, lymphotoxin-a, INF-g, GM-ulonephritis with monotypic immunoglobulin deposits.
CSF, etc.) are produced both by infiltrating and tumor
Conclusion cells [76]. These cytokines can act locally to support
growth of Hodgkin and Reed-Sternberg cells and system-The spectrum of paraneoplastic glomerulopathies has
ically as immune or pro-inflammatory mediators. Sus-dramatically expanded with the description of glomeru-
tained secretion of IL-1, IL-6, and TNF most likely ac-lar complications of CLL and plasma cell dyscrasias. The
counts for increased liver production of SAA and theoccurrence of similar glomerular lesions in benign and
development of AA-type amyloidosis in the few patientsin malignant lymphocyte or plasma-cell proliferations
with uncontrolled Hodgkin’s disease. In contrast, it is asunderlines the pathogenetic role of the secreted mole-
yet impossible to tell which cell type and which lympho-cule, mostly an immunoglobulin, irrespective of the ma-
kine are responsible for MCD. It seems likely, however,lignant or benign nature of the cell proliferation. In fact,
that proteinuria is caused by infiltrating activated T-cellsin plasma cell dyscrasias, malignancy may be conferred
rather than by tumor cells.by the severity of visceral manifestations due to light-
With regard to your second question, one approachchain deposition rather than by the cytologic features of
to the identification of the permeability factor producedthe proliferating clone. Thus, not only have hemopathy-
in some patients with Hodgkin’s disease would involveinduced glomerular diseases markedly broadened our
testing the glomerular effects of pure or fractionatedknowledge of paraneoplastic glomerulopathy, they also
serum and cells (or cell supernatants) on basement mem-have permitted us to bridge the gap at the molecular level
brane permeability. To my knowledge, only one reportbetween the cellular proliferation and the nephropathy.
addressed this important question [77]. Glomerular per-The clinician now has a valid reason to treat and reason
meability did not increase in any rats or mice injectedto hope for improvement of the glomerulopathy.
or perfused with serum or cell-culture supernatants fromIn contrast, carcinoma-associated glomerulopathies still
raise a number of questions that could be solved if we a patient with Hodgkin’s disease and MCD. Moreover,
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xenografts containing T-cells from this patient did not ative disorders. The fact that the molecular link, which
usually is a monoclonal immunoglobulin, is known ininduce proteinuria or glomerular changes in tolerant mice.
Thus, the attractive hypothesis of a disorder of T-cell the latter glomerulopathies does not rule out that they
are paraneoplastic. Nor will this adjective become inap-function in MCD, which was put forward by Shalhoub
25 years ago [78], has not yet been supported at the propriate when the putative lymphokine(s) involved in
Hodgkin’s disease-associated MCD or the antigen re-molecular level despite an increasing knowledge of alter-
ations of the cytokine network in Hodgkin’s disease [76]. leased by tumor cells in carcinoma-associated MGN are
identified. In this respect, one of the most characteristicDr. Harrington: Are there any good animal models
for paraneoplastic glomerulopathies? paraneoplastic syndromes is Schwartz-Bartter syndrome,
which occurs in small-cell lung carcinomas producingDr. Ronco: I am not aware of any animal model for
carcinoma-associated glomerulopathy. The development arginine vasopressin. I do admit, however, that the classi-
fication of myeloma cast nephropathy is difficult becauseof such a model would require grafting of carcinoma
cells from patients with paraneoplastic glomerulopathy this disease, caused by light-chain precipitation in distal
tubule lumens, occurs almost exclusively in myelomato immunodeficient mice. However, animals can die be-
fore developing proteinuria. The lack of progress in the patients with high tumor burdens [80]. Finally, I fully
agree that renal manifestations in AL amyloidosis andpathophysiology of MGN in humans seems to have dis-
couraged research in the field of paraneoplastic MGN. LCDD patients mainly depend on abnormalities of im-
munoglobulin chains that are unrelated to malignancy.It is much easier to inject mice with plasma cells produc-
ing a nephritogenic immunoglobulin. An animal model Thus the same renal disease can be observed in malig-
nant and nonmalignant conditions provided they shareof MIDD has thus been established [79]. It allowed iden-
tification of the role of amino acid substitutions in the same molecular link.
Dr. Daniel Cordonnier (Service de Ne´phrologie,V-region sequences of the light chain.
Dr. Jean-Louis Preud’homme (Laboratoire d’Immu- University Hospital, Grenoble, France): A key feature of
carcinoma-associated glomerulopathy is the disappear-nologie et d’Immunopathologie, CNRS ESA 6031, Uni-
versity Hospital, Poitiers, France): While there is virtually ance of proteinuria and other renal symptoms after re-
moval of the tumor. You said that a second renal biopsynothing to add to the very nice and thorough discussion
by Dr. Ronco, I would like to make a comment. The at the time of complete remission is usually not per-
formed for ethical reasons. Are you aware of case reportsterm “paraneoplastic” appears to be both inappropriate
and confusing. It lumps together completely unrelated demonstrating histologic remission of the renal disease?
Dr. Ronco: I know about one report of completeprocesses, the rather poorly understood lesions observed
in carcinomas and Hodgkin’s lymphoma, on the one histologic remission of MGN after resection of an adeno-
carcinoma of the ascending colon [81]. Kidney tissue washand, in which the renal disease is indeed paraneoplastic,
and lesions directly linked to monoclonal immunoglobu- available seven years after remission of the nephrotic
syndrome because a left nephroureterectomy was donelins in immunoproliferative disorders, on the other hand.
In the latter conditions, if the underlying hematologic after detection of a renal cell cancer. No evidence of
MGN was found by light microscopy, immunofluores-condition is malignant, the renal lesion relates to an in-
trinsic and major function of the proliferating cells and cence, and electron microscopy. I should stress, however,
that remission of the nephrotic syndrome occurred aboutthe relationship is direct and not lateral or indirect, as
“para” means. Do you call myeloma cast nephropathy one year after removal of the tumor and that the patient
received high-dose steroids for several months.paraneoplastic? More important, the overtly malignant
or apparently benign condition of the hemopathy is irrel- Dr. Maurice Laville (De´partement de Ne´phrologie,
Hoˆpital Edouard-Herriot, Lyon, France): Both malig-evant. Two-thirds of AL amyloidosis and one-third of
LCDD patients have no malignant disease, and yet the nant and nonmalignant lymphoid tissue proliferations
can be associated with paraneoplastic glomerulopathies.visceral lesions are the same as those in patients with
myeloma. The causes of the disease are molecular abnor- Do you think that the lymphoid tissue reaction to carci-
noma rather than the release of tumor antigens is respon-malities of immunoglobulin chains that are unrelated to
malignancy. sible for the development of proteinuria and glomerular
lesions?Dr. Ronco: I agree that the term “paraneoplastic” is
ambiguous in some instances. As I specified in my discus- Dr. Ronco: Your suggestion is very interesting, in-
deed. Solid tumors often are associated with an intensesion, this term refers to clinical manifestations that are
not directly connected to tumor mass, compression, or inflammatory reaction that can evolve into granulomas
[82], as in Hodgkin’s disease. Few cases of carcinomametastasis and that regress when the tumor is cured. In
my opinion, this definition not only fits with carcinoma- complicated by MCD have been reported [reviewed in
27]. Lymphokines produced by infiltrating lymphocytesand Hodgkin’s disease-associated glomerulopathies, but
also with glomerulopathies observed in immunoprolifer- and macrophages can increase glomerular permeability
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and cause MCD. They also can disturb immunologic ing these carcinomas, and not others, to MGN? In partic-
ular, you suggested that anti-p53 antibodies play a rolepathways leading to the production of antibodies against
tumor or self antigens and to the development of MGN. in the pathogenesis of paraneoplastic MGN. Are muta-
tions in p53 occurring with a particularly high frequencyDr. Gilbert Deray (De´partement de Ne´phologie, Hoˆ-
pital de la Pitie´-Salpeˆtrie`re, Paris, France): It has been during the evolution of lung and colonic carcinomas?
Dr. Ronco: Mutations in p53 are indeed more fre-suggested that fetal antigens expressed in carcinoma cells
are involved in the pathogenesis of paraneoplastic MGN. quent in lung (60%) and pancreatic (44%) cancers than
in any other (bladder, 34%; breast, 22%; in controls, theCould you speculate on this hypothesis?
Dr. Ronco: Carcinoembryogenic antigen (CEA) is a mutation rate is zero) [39]. Consequently, the percentage
of patients with anti-p53 antibodies is the highest in pa-good example of an antigen, expressed during embryo-
genesis in digestive tissues, that can be re-expressed in tients with lung (24%) and pancreatic (19%) cancers
(bladder, 17%; breast, 12% to 14%) [39].adulthood in a variety of conditions including cancer,
inflammatory intestinal diseases, liver diseases, chronic Dr. Jean-Daniel Sraer (De´partement de Ne´phrologie,
Hoˆpital Tenon, Paris): There is a high incidence of de-lung diseases, and heavy smoking. Indeed, CEA or CEA-
like antigen has been detected in several cancer patients novo MGN in renal transplant recipients, as compared
to the general population. Recipients of renal transplantswith MGN [33, 36, 37], but as I said, its presence in sub-
epithelial deposits can result from increased permeabil- also have an increased incidence of malignancy. What
do we know about paraneoplastic GN in these patients?ity of the glomerular basement membrane to proteins,
as shown for albumin in Heymann’s nephritis. It is not Dr. Ronco: I am not aware of any case of carcinoma-
associated glomerulopathy in patients who have receivedyet possible to implicate CEA or other tumor antigens
in the pathogenesis of paraneoplastic MGN. To address renal transplants.
Dr. Vincent Esnault (Service de Ne´phrologie-Immu-this important issue, it would be necessary to set up an
experimental model in mice or rats immunized with those nologie, University Hospital, Nantes, France): I am puz-
zled by the complement drop in your second patient,antigens.
Dr. Jean-Pierre Clauvel (Service d’Immuno-He´ma- who had organized microtubular monoclonal deposits,
as well as in several patients with HCDD. How do youtologie, Hoˆpital Saint-Louis, Paris): Your first patient
presented with a mediastinal lymph node relapse without explain complement consumption in those patients?
Dr. Ronco: Patient 2 had a transient decrease in CH50recurrence of the nephrotic syndrome. This interesting
observation suggests that the tumor mass also can con- at the time of referral, but normal C3 and C4 fractions.
Although Patient 3 with g1-HCDD had normal comple-tribute to the pathogenesis of paraneoplastic syndromes.
In my own experience of patients with diffuse mono- ment levels, signs of complement consumption were
found in three of four patients with g1-HCDD, in allclonal proliferation of CD8 T-cells and neutropenia, re-
moval of a large tumor—for instance, splenectomy—is three patients with g3-HCDD, and in none of the two
patients with g4-HCDD as yet reported [reviewed in 68].often associated with a dramatic increase of the neutro-
phil polymorphonuclear cell count. The lack of complement activation in patients with g4-
HCDD is not surprising since g4 does not activate com-Dr. Ronco: Because our first patient also received
three courses of chemotherapy after surgery, it is difficult plement. Two regions play a critical role in complement
activation: the CH2 that expresses the C1q binding site,to establish whether the absence of renal relapse was
accounted for by chemotherapy or by the lower tumor and the hinge region that confers flexibility to the immu-
noglobulin molecule [84]. I should stress that deletionmass of mediastinal lymph nodes. I agree that full-blown
expression of paraneoplastic glomerulopathies can indi- of the CH1 was found in all seven patients in whom this
anomaly was sought [68]. I am aware of two additionalrectly be linked to tumor burden in carcinoma patients.
Dr. Philippe Lesavre (De´partement de Ne´phrologie, HCDD cases with a CH1 deletion. This CH1 deletion
might increase accessibility of C1q to its binding siteHoˆpital Necker, Paris): Laure-He´le`ne Noe¨l in our group
studied the isotype of the deposited IgG in idiopathic on the CH2, and this in turn might initiate complement
activation [85].forms of MGN [83]. She found that the isotype was
restricted to IgG1 and IgG4. This finding might indicate Dr. Christian Combe (Service de Ne´phrologie, Hoˆpital
Saint-Andre´, Bordeaux, France): As you mentioned inan auto-antibody nature of the deposited IgG. Are you
aware of such a study in paraneoplastic forms of MGN? your presentation, mesangioproliferative glomerulone-
phritides have been described in some patients with Cas-Dr. Ronco: Unfortunately, I know of no study dealing
with this important issue. tleman’s disease [86], which often is associated with Ka-
posi’s sarcoma-associated herpesvirus (KSHV/HHV-8)Dr. Je´roˆme Rossert (De´partement de Ne´phrologie,
Hoˆpital Tenon, Paris): Paraneoplastic MGNs mostly oc- infection. Since high plasma levels of IL-6, a potent medi-
ator of glomerular inflammation [87], have been reportedcur during the evolution of lung carcinomas or of colonic
carcinomas. Can you speculate on the mechanisms link- in these patients [86], do you think that viral infection
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could contribute via IL-6 production to the pathogenesis association with MPGN or in the form of thrombotic
microangiopathy.of the glomerulonephritides associated with Castleman’s
With regard to your last question, the implication ofdisease? Is there any evidence for the implication of
other viruses in cancer-associated glomerulopathies isother viruses in cancer-associated glomerulopathies?
indeed plausible. Hepatitis-C virus infection is known toDr. Ronco: This question offers me the opportunity
trigger B-lymphocyte proliferation that can evolve intoto discuss both the concept and the pathophysiology of
lymphoma and be associated with cryoglobulinemicparaneoplastic glomerulopathy in the setting of a rare,
MPGN [94].polymorphic disease that can evolve as a benign disorder
Dr. Clauvel: The detection of HHV-8 in malignantor a malignancy. Castleman’s disease occurs in two forms:
and nonmalignant hemopathies indeed represents a ma-a localized, usually mediastinal lymphoid mass, and a
jor breakthrough in the pathophysiology of these dis-systemic variant that involves multiple lymphoid regions
eases. The finding of HHV-8 sequences in bone marrowand other organs. The former responds to local treat-
dendritic cells of myeloma patients [95] is a debated issue,ment, whereas multicentric Castleman’s disease has an
but it has been recently confirmed by several groups. Also,aggressive clinical course and is frequently fatal. Lesions
HHV-8 sequences have been found in bone marrow den-are classified histologically as the common hyaline-vascu-
dritic cells in AL amyloidosis (abstract, Blood 92:261a,lar type (80% to 90%) or the rarer plasma cell type
1998) and in POEMS syndrome (unpublished data).(10% to 20%) [88]. Castleman’s disease is also referred
Dr. Jean-Charles Piette (Service de Me´decine In-to as angiofollicular lymph node hyperplasia, a term that
terne, Hoˆpital de la Pitie´-Salpeˆtrie`re, Paris): We retro-points to vascular proliferation, a key feature of the
spectively looked for antibodies to HHV-8 in 13 patientsdisease. Most cases include systemic symptoms (fever,
with POEMS syndrome. Four of these patients also hadweight loss, asthenia) and signs of inflammatory activity,
Castleman’s disease. Anti-HHV-8 antibodies could beboth being caused by the lymph node lesion; all symp-
detected in only one of the 13 patients, who did not havetoms and signs disappear after surgical excision or suc-
Castleman’s disease (Papo T, unpublished data). We alsocessful medical treatment of the mass.
found very high serum levels of vEGF in eight patientsRecent data indeed suggest that excessive IL-6 pro-
with POEMS syndrome; however, vEGF levels were sim-duction by plasma cells and cells of the germinal centers
ilar in patients with (n 5 4) and without (n 5 4) renalplay a role in the genesis of systemic and renal manifesta-
involvement [96].tions of Castleman’s disease [86]. Renal complications
Dr. Clauvel: The lack of antibodies in some series ofinclude AA-type amyloidosis, MPGN, thrombotic mi-
patients with Castleman’s disease does not exclude HHV-8croangiopathy, and acute interstitial nephritis (Kazes I,
infection. In our own series, antibodies were detected in
unpublished data). Reversal of nephrotic syndrome due
90% of the patients. Such discrepant results could be
to AA-type amyloidosis [89] and resolution of MPGN explained by technical problems. Anti-HHV-8 antibodies
[90] were observed after excision of a giant axillary lymph also have been detected in myeloma patients [97]. The
node and prednisolone and cyclophosphamide therapy, absence of these antibodies could be due to the small
respectively. Relapse of Castleman’s disease occurred numbers of dendritic cells infected with HHV-8 and to
with increasing proteinuria [90]. Most likely, IL-6 is an the low copy number of virus in any individual cell [98].
important molecular link between the lymphoprolifera- Dr. Cordonnier: In your second patient with CLL-
tive disorder and glomerular lesions because IL-6 in- related glomerulopathy, subepithelial deposits had a fi-
creases SAA protein synthesis by hepatocytes [91] and brillary structure made of microtubules with a diameter
increases mesangial cell proliferation and matrix produc- of 22 nm. The size and structure are reminiscent of those
tion in vivo [87]. Castleman’s disease-associated glomer- of IgGk described in monoclonal cryoprecipitates by our
ulopathies thus fulfill all the criteria for paraneoplastic group in 1979 [99]. I would suggest that the link between
glomerulopathies although the underlying hemopathy the few blood cells that showed cytoplasmic spots of g and
often is benign. k chains and the renal deposits could have been a transient
The detection of HHV-8/KSHV in 40% of HIV-nega- cryoglobulin inducing complement consumption.
tive patients with Castleman’s disease [74] and the dem- Dr. Ronco: Although the hypothesis of a transient
onstration of viral genes encoding vIL-6, Bcl-2, and cyclins cryoglobulinemia cannot be ruled out completely, the
[92] led to the suggestion that the virus could be impli- renal lesions were not suggestive of a cryoglobulinemic
cated both in B-cell proliferation and in systemic and kidney mainly because there was no subendothelial de-
renal manifestations of Castleman’s disease. In addition, posit. In fact, the renal lesions were similar to those
the tropism of HHV-8/KSHV for endothelial cells [93] found in GOMMID [52].
and its angiogenic effects mediated by a G-protein-cou- Dr. Guy Touchard (Service de Ne´phrologie, Univer-
pled receptor and vEGF secretion [74] might account sity Hospital, Poitiers): Patient 2 is affected with the
condition we have described as GOMMID in every as-for the development of vascular lesions that occur in
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pect, including response to chemotherapy [52]. This en- late on the mechanisms responsible for this accumulation
of extracellular matrix?tity was diagnosed in five of our six patients presenting
Dr. Ronco: Zhu and associates have shown that pro-with the nephrotic syndrome associated with CLL. The
duction of matrix proteins (including type-IV collagen,sixth patient also had organized microtubular immuno-
laminin, and fibronectin) and of bioactive TGF-b wasglobulin deposits, but these deposits were not monotypic,
increased in rat mesangial cells cultured in the presenceas they contained g, m, k, and l chains. Also, GOMMID
of light chains isolated from MIDD patients [101]. Fur-was found in one patient with a benign monoclonal gam-
thermore, anti-TGF-b antibody abolished the inhibitionmopathy (MGUS) and in three patients without overt
of cell proliferation and the increase of extracellular ma-plasma cell dyscrasia. We could not detect the deposited
trix protein production caused by these light chains.M-component in the serum and the urine even by the
These findings were not obtained when mesangial cellssensitive Western blotting method in two of five patients
were exposed to human albumin or to two other lightwith GOMMID and CLL and in two of four patients
chains previously characterized to be tubulopathic. To-with GOMMID not linked with CLL.
gether with overexpression of TGF-b in affected glomer-Dr. Preud’homme: One may regret that in Patient 2,
uli of MIDD patients, these data support a key role forcirculating M-components were not sought by Western
TGF-b in extracellular matrix accumulation.blotting, which is more sensitive than immunofixation
Dr. Rossert: If TGF-b is a key player, would you notby several orders of magnitude. In addition, cytoplasmic
expect some accumulation of type-I collagen?immunofluorescence and electron microscopic studies of
Dr. Ronco: Certainly, yes. I should stress, however,the lymphocytes could have provided evidence of a direct
that matrix accumulation can result from increased syn-relationship between CLL and renal deposits.
thesis but also from decreased degradation of matrixDr. Ronco: Patient 2 was referred to us several years
components. Since type-I and type-IV collagens are de-ago, before Western blotting was commonly used as a
graded by different metalloproteases, one could suggestsensitive method for detecting M-components. We could
that those degrading type-I collagen (interstitial colla-not identify with certainty whether the cytoplasmic spots
genases) are upregulated in glomeruli of MIDD patients.of g and k chains were localized in lymphocytes; neither
Dr. Preud’homme: Nodular glomerulosclerosis is ob-could we detect organized deposits in lymphocytes by
served in 100% of HCDD, approximately 60% of k LCDD,electron microscopy because of the small number of cir-
and very few l LCDD cases. I would be most interestedculating lymphocytes during chemotherapy.
in the interpretation of these apparently isotype-relatedDr. Touchard: Concerning the classification of gran-
differences by our nephrologist colleagues.ular (non-organized) monoclonal immunoglobulin de-
Dr. Ronco: A first explanation is that the duration
posits, it seems important to distinguish two types of
of the underlying hematologic disease may be longer in
deposits according to their localization: Randall-type patients who develop nodular glomerulosclerosis. This
granular deposits affecting glomerular and tubular base- hypothesis is supported by the apparently lower preva-
ment membranes, and non-Randall-type granular depos- lence of myeloma in HCDD than in LCDD patients.
its affecting the subepithelial and subendothelial spaces Second, the fibrogenetic potential might depend on the
of glomerular capillary wall and often the mesangium isotype and surface properties of the M-component. The
but not the peritubular area. We recently studied a patient mesangial cell most likely is the main culprit of extracel-
with type-III MPGN and granular non-Randall-type mono- lular matrix accumulation. Because the pattern of in-
clonal l light-chain dense deposits in mesangial, sub- creased matrix components is similar to that observed
epithelial, and intramembranous areas. The monoclonal in diabetes and also because 20% to 30% of light chains
l light chain activated the alternative pathway of comple- isolated from MIDD patients are glycosylated, it has
ment, probably by interacting directly with factor H as been suggested that fibrogenetic light chains could bind
previously reported [100]. Certainly LCDD, HCDD, and to mesangial cells via the receptor for advanced glycosyl-
LHCDD are the most frequent forms of MIDD, but ation end products (AGEs) and thereby increase matrix
there is still room for other variants of the disease. protein production through PDGF [102]. The varying
Dr. Ronco: We also have encountered cases of MIDD fibrogenetic potential of light and heavy chains might be
with non-organized granular deposits restricted to the accounted for by different abilities of the M-component
glomerulus. I agree that MIDD can be more heteroge- to bind mesangial cell receptors and to trigger intracellu-
neous than expected. Patients with MIDD should be lar pathways, leading to increased transcription of some
classified according to the type of deposited M-component matrix protein genes.
and to the precise location of the deposits. Dr. Bruno Moulin (Service de Ne´phrologie, Hoˆpital
Dr. Rossert: During the course of MIDD, there is Civil, Strasbourg, France): As you stated, MIDD is a
deposition of a monoclonal component but also a striking systemic, life-threatening disease whether it occurs in
the setting of a benign or a malignant plasma cell prolifer-accumulation of extracellular matrix. Could you specu-
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